FDA Approves BRENZAVVY — TheracosBio, LLC

TheracosBio, LLC received FDA approval for the oral diabetes agent BRENZAVVY, a milestone that establishes its presence in the competitive SGLT2 inhibitor market and is likely to capture investor attention as the company vies against major pharmaceutical players for market share.